Current Cancer Drug Targets
Volume 22, 11 Issues, 2022
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
Contents
Current Cancer Drug Targets , Volume 9 - Number 6
Molecular Features, Markers, Drug Targets, and Prospective Targeted Therapeutics in Cardiac Myxoma
, 9(6): 705 - 716Debmalya Barh, Anil Kumar, Suvro Chatterjee and Triantafillos Liloglou
DOI: 10.2174/156800909789271549
Caspase-Independent Pathways of Programmed Cell Death: The Unraveling of New Targets of Cancer Therapy?
, 9(6): 717 - 728C. Constantinou, K. A. Papas and A. I. Constantinou
DOI: 10.2174/156800909789271512
Sunitinib (SUTENT, SU11248) Suppresses Tumor Growth and Induces Apoptosis in Xenograft Models of Human Hepatocellular Carcinoma
, 9(6): 738 - 747H. Huynh, V. C. Ngo, S. P. Choo, D. Poon, H. N. Koong, C. H. Thng, H. C. Toh, L. Zheng, L. C. Ong, Y. Jin, I. C. Song, A. P.C. Chang, H. S. Ong, A. Y.F. Chung, P. K.H. Chow and K. C. Soo
DOI: 10.2174/156800909789271530
Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy
, 9(6): 748 - 760J. van der Veeken, S. Oliveira, R. M. Schiffelers, G. Storm, P.M.P. van Bergen en Henegouwen and R. C. Roovers
DOI: 10.2174/156800909789271495
Heat Shock Protein 90 – a Potential Target in the Treatment of Human Acute Myelogenous Leukemia
, 9(6): 761 - 776H. Reikvam, E. Ersvær and O. Bruserud
DOI: 10.2174/156800909789271486
Increased Tumor Oxygenation and Drug Uptake During Anti-Angiogenic Weekly Low Dose Cyclophosphamide Enhances the Anti-Tumor Effect of Weekly Tirapazamine (Supplementry Material)
, 9(6): 777 - 788J. C. Doloff, N. Khan, J. Ma, E. Demidenko, H. M. Swartz and Y. Jounaidi
DOI: 10.2174/156800909789271503
Editor-in-Chief
Ruiwen Zhang
Center for Drug Discovery
University of Houston
Houston, TX
(USA)
Biography
Center for Drug Discovery
University of Houston
Houston, TX
Biography
Biography of Ruiwen Zhang
Ruiwen Zhang is the Robert L. Boblitt Endowed Professor in Drug Discovery and Director of the Drug Discovery Institute at the University of Houston. With over 30 years of experience in the field of biomedical research, particularly in the area of clinical pharmacology and therapeutics, pharmaceutical and toxicological research, Dr. Zhang’s research has been continuously funded by NIH and DoD, and other agencies. He has published more than 230 papers, 2 books, and more than 50 invited reviews/book chapters as well as more than 180 meeting abstracts. For his outstanding contributions in pharmaceutical sciences, Dr. Zhang was elected as a Fellow of American Association for the Advancement of Science (AAAS) in 2009. Dr. Zhang is recently elected as Fellow of National Academy of Inventors (2018).
COPE Compliant
About the Journal
⇨ Journal Home⇨ Editorial Policies⇨ Fabricating and Stating False Information⇨ Research Misconduct⇨ Post Publication Discussions and Corrections⇨ Allegations from Whistleblowers⇨ Editorial Board⇨ Meet the Executive Guest Editor(s)⇨ Board Recruitment Workflow⇨ Short Guide⇨ Join Editorial Board⇨ Indexing Information⇨ Announcements⇨ Endorsements⇨ Authors' Comments
For Authors
For Librarians & Readers
Quick Links
Advertisement
Webmaster Contact: info@benthamscience.net